Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 2221 to 2235 of 2854 results for process

  1. Twin and triplet pregnancy (NG137)

    This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.

  2. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

    This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.

  3. Thrombophilia [ID393]

    Discontinued Reference number: GID-TAG374

  4. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development Reference number: GID-TA11273 Expected publication date: TBC

  5. Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]

    Discontinued Reference number: GID-TA10443

  6. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

  7. Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088

    Discontinued Reference number: GID-TA11702

  8. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued Reference number: GID-TA11261

  9. Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

    Discontinued Reference number: GID-TA10464

  10. Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

    Discontinued Reference number: GID-TA10543

  11. Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]

    Discontinued Reference number: GID-TA10875

  12. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued Reference number: GID-TA10499

  13. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued Reference number: GID-TA10149

  14. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development Reference number: GID-TA10858 Expected publication date: TBC

  15. ALXN1840 for treating Wilson disease [ID6422]

    In development Reference number: GID-TA11449 Expected publication date: TBC